Artelo Biosciences Expands Into Glaucoma With Fully Funded Clinical Study; Stock Surges Over 50%

Artelo Biosciences announced two clinical developments that broaden its pipeline and mark its entry into the glaucoma market, triggering a sharp rally in the stock. The moves diversify the company’s clinical footprint and should improve investor sentiment by adding exposure to the fast-growing glaucoma opportunity.

Analysis

Artelo Biosciences announced two clinical developments that broaden its pipeline and mark its entry into the glaucoma market, triggering a sharp rally in the stock. The moves diversify the company’s clinical footprint and should improve investor sentiment by adding exposure to the fast-growing glaucoma opportunity.